Morgan Stanley Initiates Coverage On IO Biotech with Overweight Rating, Announces Price Target of $21
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops disruptive immune modulating anti-cancer therapies in Denmark. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine...
IPO intraday trading strategy idea
The share price is rising and gonna continue this trend today.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price today.
So I opened a long position from $17,13;
stop-loss — $14,66;
take-profit — $24,54/MOC price.
Do not view this idea as a...
